Search Results

Featured Stories

Toggle

Showing 10 of 720 results

Teva Reports First Quarter 2021 Financial Results

Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full year 2021 business outlook...

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

  TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020. This press release...

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

January 12, 2021 /3BL Media/  - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced long-term environmental sustainability commitments and targets to provide direction and drive...

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release S

Study met its primary efficacy endpoint of delaying time to relapse TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext:...

Teva Reports Third Quarter 2020 Financial Results

Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net revenues of $16.5-16.8 billio...

Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio

Teva’s Digital Inhaler Portfolio Now Powered by AWS TEL AVIV, Israel & PARSIPPANY, N.J. & SAN ANTONIO--(BUSINESS WIRE)-- Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd....

Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disopro

  TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the availability of t...

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

TEL AVIV, Israel & REYKJAVIK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates.

Teva Reports Second Quarter 2020 Financial Results

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2020.